WO2022119300A1 - 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물 - Google Patents
안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물 Download PDFInfo
- Publication number
- WO2022119300A1 WO2022119300A1 PCT/KR2021/017964 KR2021017964W WO2022119300A1 WO 2022119300 A1 WO2022119300 A1 WO 2022119300A1 KR 2021017964 W KR2021017964 W KR 2021017964W WO 2022119300 A1 WO2022119300 A1 WO 2022119300A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solid dispersion
- weight
- acid
- olaparib
- parts
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 239000007962 solid dispersion Substances 0.000 title claims abstract description 81
- 229960000572 olaparib Drugs 0.000 title claims abstract description 79
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 title claims abstract 8
- 229920000193 polymethacrylate Polymers 0.000 claims abstract description 21
- 239000003085 diluting agent Substances 0.000 claims description 24
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 20
- 229920000642 polymer Polymers 0.000 claims description 19
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 18
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 18
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 18
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 15
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 15
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 12
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 12
- 150000007524 organic acids Chemical class 0.000 claims description 12
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000001530 fumaric acid Substances 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 238000001694 spray drying Methods 0.000 claims description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 6
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 5
- 229920001249 ethyl cellulose Polymers 0.000 claims description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
- 239000011976 maleic acid Substances 0.000 claims description 5
- 239000001630 malic acid Substances 0.000 claims description 5
- 235000011090 malic acid Nutrition 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- 235000010981 methylcellulose Nutrition 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229920002301 cellulose acetate Polymers 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 3
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims description 3
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 3
- 229920006317 cationic polymer Polymers 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- 229920006184 cellulose methylcellulose Polymers 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 39
- 239000003814 drug Substances 0.000 abstract description 39
- 238000003860 storage Methods 0.000 abstract description 8
- 229920003174 cellulose-based polymer Polymers 0.000 abstract description 2
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical group FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 description 71
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 18
- 238000009472 formulation Methods 0.000 description 18
- 238000004090 dissolution Methods 0.000 description 17
- 238000000576 coating method Methods 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- -1 olaparib anhydride Chemical class 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 9
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 9
- 235000011087 fumaric acid Nutrition 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 8
- 229920003148 Eudragit® E polymer Polymers 0.000 description 7
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229960001681 croscarmellose sodium Drugs 0.000 description 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 150000003839 salts Chemical group 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 238000000634 powder X-ray diffraction Methods 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 229920003119 EUDRAGIT E PO Polymers 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 239000011247 coating layer Substances 0.000 description 4
- 229920001477 hydrophilic polymer Polymers 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000011118 polyvinyl acetate Substances 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920003083 Kollidon® VA64 Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229920006125 amorphous polymer Polymers 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 229940023144 sodium glycolate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 229920003149 Eudragit® E 100 Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000013078 crystal Chemical group 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940100352 lynparza Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical class C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a solid dispersion composition of olaparib with improved stability and bioavailability, and more particularly, it contains olaparib, a poorly soluble drug, a polymethacrylate copolymer, and a cellulose-based polymer as essential components, and storage
- the present invention relates to an olaparib solid dispersion having excellent stability and thermal stability, uniform drug release under various pH conditions in the body, and improved bioavailability, and an oral composition comprising the same.
- Olaparib a phthalazinone derivative drug
- Olaparib has weak acidity with a pKa of 12.07 and is a poorly soluble substance with very low water solubility (0.1 ⁇ 0.13mg/ml) in the physiological pH range. Since the low solubility and bioavailability of the drug active ingredient is a problem in drug formulation, various methods such as changing the crystalline form or preparing a salt form have been attempted.
- Lynparza TM capsule a commercially available formulation, also uses GelucireTM 44/14, a lipid excipient, to improve drug solubility, but the drug content in the formulation is 10%. There is the inconvenience of having to take 8 capsules at a time.
- Another object of the present invention is to provide an oral composition containing olaparib having excellent storage stability and thermal stability, exhibiting uniform drug release under various pH conditions in the body, and having improved bioavailability, and a method for preparing the same.
- One aspect of the present invention is olaparib; polymethacrylate copolymer; And cellulosic polymer; relates to a solid dispersion comprising a.
- the polymethacrylate copolymer is a cationic polymer having dimethylaminoethyl methacrylate.
- the polymethacrylate copolymer is poly(butylmethacrylate-co-(2-dimethylaminoethyl)methacrylate-co-methylmethacrylate).
- the cellulosic polymer is selected from the group consisting of hydroxypropylmethylcellulose, microcrystalline cellulose, hydroxypropylcellulose, carboxymethylcellulose, ethylcellulose, cellulose acetate, methylcellulose, and mixtures thereof.
- the solid dispersion further comprises D- ⁇ -tocopheryl polyethylene glycol succinate.
- the solid dispersion is obtained by spray drying.
- the solid dispersion comprises amorphous olaparib.
- Another aspect of the present invention (1) dissolving or dispersing olaparib in a solvent together with a polymethacrylate copolymer; (2) adding and mixing a cellulosic polymer to the solution or dispersion obtained in step (1); and (3) removing the solvent from the solution or dispersion obtained in step (2).
- the removal of the solvent is performed by spray drying.
- the solid dispersion; pharmaceutically acceptable organic acids; And a pharmaceutically acceptable diluent it relates to an oral composition comprising.
- the pharmaceutically acceptable organic acid is selected from the group consisting of acrylic acid, tartaric acid, citric acid, malic acid, maleic acid, fumaric acid, acetic acid, succinic acid, lactic acid, succinic acid, malonic acid, glutaric acid and mixtures thereof.
- the pharmaceutically acceptable diluent is a water-soluble diluent.
- the water-soluble diluent is selected from the group consisting of sugar alcohols, sugars, and mixtures thereof.
- the oral composition is for the treatment of cancer.
- Another aspect of the present invention relates to a method for preparing an oral composition, comprising mixing the solid dispersion with a pharmaceutically acceptable organic acid and a pharmaceutically acceptable diluent.
- the solid dispersion disclosed in the present invention and the oral composition comprising the same are excellent in storage stability and thermal stability by stably amorphizing olaparib, and exhibit uniform drug release under various pH conditions in the body, olaparib
- By increasing the solubility and dissolution rate of the drug it is possible to improve the bioabsorption rate of the drug and improve the bioavailability.
- the content of the drug in the formulation is increased to reduce the number of units of the formulation to be taken at a time, thereby improving patient compliance, and furthermore, more advantageous composition and manufacturing process application for formulation
- productivity such as manufacturing and packaging.
- Example 1 is an XRPD pattern of the solid dispersion and olaparib API (active ingredient) prepared in Examples 1, 2 and Comparative Example 1, respectively, while the olaparib API itself used for preparing the solid dispersion was in a crystalline form. It shows that olaparib included in the solid dispersions prepared in Examples 1, 2 and Comparative Example 1 were all amorphous.
- Example 2 shows the dissolution patterns of the tablets prepared in Example 3 in a pH 1.2 solution, a pH 4.0 solution, a pH 6.8 solution, and water (distilled water, DW).
- Example 3 shows the dissolution patterns of the tablets prepared in Example 4 in a pH 1.2 solution, a pH 4.0 solution, a pH 6.8 solution, and water (distilled water, DW).
- One aspect of the present invention is olaparib; polymethacrylate copolymer; And cellulosic polymer; relates to a solid dispersion comprising a.
- the "olaparib” may be an olaparib base (a free base drug without a separate salt), a pharmaceutically acceptable salt of a drug, an isomer of a drug, or a mixture thereof. It may also be one which in each case forms various hydrates, and in each case various crystalline forms. For example, it may be a crystalline form of olaparib hydrate (eg, monohydrate) or olaparib anhydride, or an amorphous form thereof or a mixture thereof.
- the olaparib may be in various forms, for example, it may be in an undifferentiated form with a size of several to several tens of micrometers, and more preferably, it may be in an undifferentiated form with a size of several micrometers (eg, 1 to 9 micrometers in size). And, more preferably, it may be in a nano-sized form with a size of several hundred nanometers (eg, a size of 100 to 900 nanometers). As the particle size of the drug decreases, the dissolution rate may be improved, thereby increasing solubility and bioavailability.
- the polymethacrylate copolymer may be a cationic polymer with dimethyl-aminoethyl methacrylate, and more specifically, poly(butyl methacrylate-co). -(2-dimethylaminoethyl)methacrylate-co-methylmethacrylate).
- each monomer may form a polymer in a molar ratio of 1:2:1.
- the polymethacrylate copolymer may be Eudragit® E PO (Evonik, Germany) or Eudragit® E 100 (Evonik, Germany).
- Eudragit® E polymer is usually a coating base, and when it is necessary to protect the drug from moisture or the patient's adherence to the medication is poor, it encapsulates the sensitive drug or masks the taste and smell of the drug to alleviate the patient's reluctance to take it, It is used for the purpose of providing a smooth and shiny surface so that the drug can be easily swallowed, but in the present invention, it is used as a polymer to improve the solubility and bioavailability of olaparib.
- the weight average molecular weight of the polymethacrylate copolymer may be 3,000 to 200,000, or 5,000 to 150,000, or 10,000 to 100,000, or 20,000 to 80,000, or 37,000 to 57,000 g/mole. If the weight average molecular weight of the polymethacrylate copolymer is less than 3,000 g/mole, there is a fear that the effect of improving water solubility may be low, and if the weight average molecular weight exceeds 200,000 g/mole, there is a fear that disintegration may be delayed.
- the state of the polymethacrylate copolymer is not particularly limited, but may be in a granular or powder state.
- the amount of the polymethacrylate copolymer included in the solid dispersion of the present invention based on 1 part by weight of olaparib, 0.05 parts by weight or more, 0.1 parts by weight or more, 0.15 parts by weight or more, 0.2 parts by weight or more or 0.5 parts by weight or more, and also 10 parts by weight or less, 9 parts by weight or less, 8 parts by weight or less, 7 parts by weight or less, 6 parts by weight or less, 5 parts by weight or less, 4 parts by weight or less, 3 parts by weight or less; It may be 2 parts by weight or less, but is not limited thereto.
- the solid dispersion of the present invention based on 1 part by weight of olaparib, 0.05 to 10 parts by weight, 0.1 to 6 parts by weight, 0.2 to 4 parts by weight, or 0.5 to 2 parts by weight of the polymethacrylate copolymer may be included as a part. If the content of the polymethacrylate copolymer in the solid dispersion is less than the above-mentioned lower limit range, the effect of improving the solubility and bioavailability of olaparib may be insufficient, and if it is outside the above-mentioned upper limit, the formulation (for example, , capsules or tablets) may become large, which may cause discomfort when taken by the patient.
- the formulation for example, , capsules or tablets
- the cellulosic polymer is hydroxypropylmethylcellulose (HPMC), microcrystalline cellulose (MCC), hydroxypropylcellulose (hydroxypropylcellulose, HPC), carboxymethylcellulose (carboxymethylcellulose, CMC), It is selected from the group consisting of ethylcellulose (EC), cellulose acetate (CA), methylcellulose (methylcellulose) and mixtures thereof, more specifically hydroxypropylmethylcellulose (HPMC), microcrystalline cellulose ( MCC), hydroxypropylcellulose (HPC), carboxymethylcellulose (CMC) and mixtures thereof, and more specifically, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC) and selected from the group consisting of mixtures thereof, most preferably hydroxypropylmethylcellulose (HPMC).
- HPMC hydroxypropylmethylcellulose
- MCC microcrystalline cellulose
- HPC hydroxypropylcellulose
- HPC carboxymethylcellulose
- HPMC hydroxypropylmethylcellulose
- HPMC hydroxypropylmethylcellulose
- HPMC
- the amount of the cellulosic polymer included in the solid dispersion of the present invention may be 0.05 parts by weight or more, 0.1 parts by weight or more, 0.15 parts by weight or more, or 0.2 parts by weight or more, based on 1 part by weight of olaparib. , also 10 parts by weight or less, 9 parts by weight or less, 8 parts by weight or less, 7 parts by weight or less, 6 parts by weight or less, 5 parts by weight or less, 4 parts by weight or less, 3 parts by weight or less, 2 parts by weight or less, or 1 part by weight may be less than or equal to, but is not limited thereto.
- the solid dispersion of the present invention based on 1 part by weight of olaparib, 0.05 to 10 parts by weight of the cellulosic polymer, or 0.1 to 6 parts by weight, 0.2 to 4 parts by weight, or 0.2 to 1 parts by weight may include If the content of the cellulosic polymer in the solid dispersion is less than the above-mentioned lower limit range, the effect of improving the temperature stability of the solid dispersion may be insufficient. can affect
- the solid dispersion of the present invention may further include a hydrophilic polymer other than the cellulosic polymer.
- polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer eg Soluplus®
- polyvinylpyrrolidone PVP
- polyvinyl acetate PVA
- polyvinyl alcohol polymers of acrylic acid and its salts
- vinylpyrrolidone-vinylacetate copolymer eg Kollidon® VA64, BASF
- Polycoat IR gelatin, guar gum , at least one selected from the group consisting of partially hydrolyzed starch, alginate, xanthan, and mixtures thereof may be used, but the present invention is not limited thereto.
- the additional hydrophilic polymer when used, it is, based on 1 part by weight of olaparib, for example, 0.01 to 10 parts by weight, or 0.1 to 7 parts by weight, or 0.1 to 5 parts by weight, or It may be included in the solid dispersion in an amount of 0.1 to 3 parts by weight, but is not limited thereto.
- the solid dispersion may further include D- ⁇ -tocopheryl polyethylene glycol succinate (Vitamin E TPGS or TPGS).
- D- ⁇ -tocopheryl polyethylene glycol succinate Vitamin E TPGS or TPGS.
- the TPGS may be included in the solid dispersion in an amount of, for example, 0.001 to 2 parts by weight, 0.001 to 1 parts by weight, 0.005 to 1 parts by weight, or 0.01 to 0.1 parts by weight, based on 1 part by weight of olaparib. If the content of TPGS is less than the above-mentioned lower limit range, the degree of improvement in solubility and bioavailability of olaparib may be insignificant, and thus the effect may be reduced. , it may cause difficulties in film formation and storage.
- the solid dispersion may be spray dried.
- the solid dispersion is not in the form of a coating on the inert core, so it can be used to prepare a tablet so that more olaparib can be contained in a tablet of as small a size as possible, and the disintegration rate and dissolution rate are rapidly increased or decreased. phenomenon can be prevented.
- the solid dispersion is amorphous.
- the solubility is increased compared to the crystalline form, and thus the bioabsorption rate is higher.
- solid dispersion used in the present invention refers to a form in which an object to be dispersed (generally a drug) is dispersed in an amorphous polymer (continuous phase) in a crystalline or amorphous form. More preferably, the amorphous drug is dispersed in an amorphous polymer.
- the solid dispersion generally contains a drug and a polymer, and in some cases may contain other drug additives such as surfactants, plasticizers, and disintegrants.
- the solid dispersion comprises amorphous olaparib.
- the solid dispersion does not include a surfactant.
- the solid dispersion may further include a surfactant.
- the surfactant may be, for example, an anionic surfactant.
- Anionic surfactants include sodium dodecyl sulfate, sodium lauryl sulfate, sodium N-lauroyl sarcosylate, N-long-chain acyl glutamate, sucrose fatty acid ester, polyoxyethylene hydrogenated castor oil, sorbitan fatty acid ester, polyoxyethylene and It may be a copolymer of polyoxypropylene or a combination thereof, or sodium dodecyl sulfate.
- the surfactant is based on 1 part by weight of olaparib, for example, in an amount of 0.0001 to 1 part by weight, or 0.0005 to 0.5 part by weight, or 0.001 to 0.1 part by weight, or 0.001 to 0.01 part by weight, or 0.001 to 0.005 part by weight.
- olaparib for example, in an amount of 0.0001 to 1 part by weight, or 0.0005 to 0.5 part by weight, or 0.001 to 0.1 part by weight, or 0.001 to 0.01 part by weight, or 0.001 to 0.005 part by weight.
- the solvent used in the solution for preparing the solid dispersion may be a water-miscible organic solvent, water, or a mixture thereof.
- a water-miscible organic solvent such as alcohol, acetone, tetrahydrofuran, acetic acid, acetonitrile, dioxane, and combinations thereof may be used, but is not limited thereto.
- the water-miscible organic solvent may be, for example, a lower alcohol having 1 to 5 carbon atoms, acetone or a mixture thereof, or ethanol, acetone or a mixture thereof, or ethanol.
- the thickness of the coating layer may be measured by a scanning electron microscope (SEM) or the like after cutting the cross section of the coated particles. At this time, it is possible to check the average thickness by measuring 5 or more and averaging them.
- the average thickness of the coating layer is 10 ⁇ m or more and 500 ⁇ m or less, or 20 ⁇ m or more and 400 ⁇ m or less, or 50 ⁇ m or more and 300 ⁇ m or less, or 80 ⁇ m or more and 200 ⁇ m or less.
- the average thickness of the coating layer is thinner than the above range, the drug content in the particles is lowered and a large amount of inert core is required, so there is a risk that the formulation becomes large.
- the desired purpose cannot be achieved due to delays and excessive processing time.
- various biologically inactive ingredients may be additionally used for additional purposes such as coating efficiency, drug stability, appearance, color, protection, maintenance, bonding, performance improvement, manufacturing process improvement, etc. .
- Another aspect of the present invention (1) dissolving or dispersing olaparib in a solvent together with a polymethacrylate copolymer; and (2) adding and mixing a cellulosic polymer to the solution or dispersion obtained in step (1); and (3) removing the solvent from the solution or dispersion obtained in step (2).
- the solvent used to prepare the solid dispersion may be a water-miscible organic solvent, water, or a mixture thereof, and may include a supercritical fluid.
- the water-miscible organic solvent for example, alcohol, acetone, tetrahydrofuran, acetic acid, acetonitrile, dioxane, and combinations thereof may be used, but is not limited thereto.
- the water-miscible organic solvent may be, for example, a low-cost alcohol having 1 to 5 carbon atoms, acetone or a mixture thereof, or ethanol, acetone or a mixture thereof, or ethanol.
- the removal of the solvent may be performed using vacuum drying, spray drying, tray drying, freeze drying and other drying techniques, and in one embodiment, the removal of the solvent is performed by spray drying.
- a spray dryer, a fluidized bed dryer, or other dryers may be used for spray drying.
- the solid dispersion prepared as described above may be mixed with other additional components to form powders and granules, or the mixture may be tableted to be tableted, or encapsulated by filling into capsules.
- the crystalline drug olaparib is prepared as an amorphous solid dispersion, solubility and dissolution rate increase, thereby improving bioavailability, and furthermore, polymethacrylate copolymer and cellulosic polymer are used together By doing so, the physical stability of the solid dispersion can be improved.
- the above-described solid dispersion of the present invention comprises pharmaceutically acceptable organic acids; And a pharmaceutically acceptable diluent; it relates to an oral composition comprising.
- the oral composition may be for cancer treatment.
- the cancer may be selected from breast cancer and ovarian cancer.
- Another aspect of the present invention relates to a method for preparing an oral composition, comprising mixing the solid dispersion with a pharmaceutically acceptable organic acid and a pharmaceutically acceptable diluent.
- composition for oral use may be in the form of a solid oral preparation, in particular a tablet or capsule, in the form of, for example, a tablet, capsule, granule, or powder.
- the oral composition is a tablet.
- the content of the solid dispersion in the oral composition is 0.01 parts by weight or more, 0.05 parts by weight or more, 0.1 parts by weight or more, 0.15 parts by weight or more, 0.2 parts by weight or more, based on 1 part by weight of the oral composition. , may be 0.25 parts by weight or more or 0.3 parts by weight or more, and may be 0.9 parts by weight or less, 0.85 parts by weight or less, 0.8 parts by weight or less, 0.75 parts by weight or less, or 0.7 parts by weight or less, but is not limited thereto.
- the content of the solid dispersion in the oral composition exceeds the above range, the size of the tablet may become too large, and on the contrary, if it is too short of the above range, it may be difficult to stably achieve a target bioabsorption rate.
- the pharmaceutically acceptable organic acid is selected from the group consisting of tartaric acid, citric acid, malic acid, maleic acid, fumaric acid, acetic acid, succinic acid, lactic acid, succinic acid, malonic acid, glutaric acid, and mixtures thereof, and more specifically is selected from the group consisting of malic acid, maleic acid, tartaric acid, citric acid, fumaric acid and mixtures thereof, more specifically selected from the group consisting of fumaric acid, maleic acid, malic acid and mixtures thereof, and most preferably fumaric acid.
- the pharmaceutically acceptable organic acid content in the oral composition is 0.01 parts by weight or more, 0.02 parts by weight or more, 0.03 parts by weight or more, 0.04 parts by weight or more, or 0.05 based on 1 part by weight of the oral composition. It may be more than or equal to 0.5 parts by weight, and may be less than or equal to 0.5 parts by weight, less than or equal to 0.45 parts by weight, less than or equal to 0.4 parts by weight, less than or equal to 0.35 parts by weight, less than or equal to 0.3 parts by weight or less than or equal to 0.2 parts by weight, but not limited thereto. If the pharmaceutically acceptable organic acid content in the oral composition exceeds the above range too much, it may affect the stability of the formulation, and on the contrary, if it is too short of the above range, the stability of the formulation may deteriorate due to pH change.
- the pharmaceutically acceptable diluent may be a water-soluble diluent or a water-insoluble diluent, for example, lactose (anhydrous or hydrate, for example monohydrate), cellulose powder, microcrystalline cellulose, silicified microcrystalline cellulose, di Calcium phosphate, tricalcium phosphate, magnesium trisilicate, low-substituted hydroxypropylcellulose (L-HPC), starch, pregelatinized starch, mannitol, maltitol, sorbitol, xylitol, lactose, dextrose, maltose, sucrose, glucose , may be one or more selected from the group consisting of fructose, maltodextrin, and mixtures thereof, but is not limited thereto.
- lactose anhydrous or hydrate, for example monohydrate
- cellulose powder microcrystalline cellulose
- silicified microcrystalline cellulose silicified microcrystalline cellulose
- di Calcium phosphate tricalcium
- the pharmaceutically acceptable diluent is a water-soluble diluent.
- the water-soluble diluent is selected from the group consisting of sugar alcohols, sugars, and mixtures thereof.
- the sugar alcohol may be mannitol, maltitol, sorbitol, xylitol, or a combination thereof, and the sugar is lactose, dextrose, maltose, sucrose, glucose, fructose, maltodextrin, or a combination thereof.
- the water-insoluble diluent is selected from the group consisting of microcrystalline cellulose, silicified microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, low-substituted hydroxypropyl cellulose, starch, pregelatinized starch, and mixtures thereof. There may be more than one type.
- the oral composition may not include a water-insoluble diluent.
- the pharmaceutically acceptable diluent content in the oral composition is 0.01 parts by weight or more, 0.03 parts by weight or more, 0.05 parts by weight or more, 0.07 parts by weight or more, or 0.1 based on 1 part by weight of the oral composition. It may be more than 0.5 parts by weight, and may be less than or equal to 0.5 parts by weight, less than 0.45 parts by weight, less than 0.4 parts by weight, less than 0.35 parts by weight, or less than 0.3 parts by weight, but is not limited thereto.
- the content of the pharmaceutically acceptable diluent in the oral composition exceeds the above range, the tablet becomes large and may cause inconvenience to the patient when taking it. It is difficult to manufacture into tablets.
- the oral composition of the present invention may further include one or more pharmaceutically acceptable additives other than the aforementioned components (ie, a pharmaceutically acceptable organic acid and a pharmaceutically acceptable diluent).
- the pharmaceutically acceptable one or more additional additives may be, for example, a disintegrant, a lubricant, a surfactant, a coating base, or a combination thereof.
- the disintegrant is, for example, croscarmellose sodium (CrosCMC-Na), carboxymethylcellulose, crospovidone (crosslinked polyvinylpyrrolidone), L-HPC (low-substituted hydroxypropylcellulose) , starch (wheat, rice, corn or potato starch), sodium carboxymethyl starch, sodium glycolate of potato starch, partially hydrolyzed starch, and mixtures thereof. it is not Preferably, it may be croscarmellose sodium (CrosCMC-Na), sodium glycolate of starch, L-HPC (low-substituted hydroxypropyl cellulose), or a mixture thereof.
- the disintegrant may be used in an amount of, for example, 1 to 30 parts by weight, preferably 2 to 20 parts by weight, based on 100 parts by weight of the total tablet weight. If the disintegrant is less than the above-mentioned lower limit range, there may be a problem with the dissolution rate delay due to the disintegration rate delay, and if it is outside the above-mentioned upper limit range, there may be problems in productivity, such as tableting failure.
- the lubricant is, for example, magnesium stearate, fumaric acid, stearic acid, calcium stearate, sodium stearyl fumarate, polyethylene glycol, starch (wheat, rice, corn or potato starch), talc, highly dispersed type (colloid type) It may be at least one selected from the group consisting of silica, magnesium oxide, magnesium carbonate, glyceryl behenate, glyceryl monostearate, silicon dioxide, calcium silicate, magnesium silicate, and mixtures thereof, but is not limited thereto. . Preferably, it may be magnesium stearate.
- the lubricant is, for example, in an amount of 0.1 to 3 parts by weight, preferably in an amount of 0.2 to 3 parts by weight, more preferably in an amount of 0.5 to 2 parts by weight, based on 100 parts by weight of the total formulation weight.
- the lubricant is less than the above-mentioned lower limit range, there may be problems in productivity such as tableting disorder, and if it is outside the above-mentioned upper limit range, there may be problems in dissolution delay or productivity.
- the surfactant is, for example, an anionic surfactant (sodium lauryl sulfate, docusate sodium, etc.), a cationic surfactant (cetyl trimethylammonium bromide (CTAB), benzethonium chloride, etc.), a nonionic surfactant ( Polysorbate 80, 40 and 20, lauryl dimethylamine N-oxide (LDAO), etc., Cremophor RH40 TM , polyoxyethylene stearate and poloxamer, and may be at least one selected from the group consisting of mixtures thereof, but limited thereto No. Preferably, it may be sodium lauryl sulfate.
- the surfactant is used in an amount of, for example, 0.1 to 10 parts by weight, preferably 0.5 to 7 parts by weight, more preferably 1 to 5 parts by weight based on 100 parts by weight of the total formulation weight.
- the surfactant is less than the above-mentioned lower limit range, it is difficult to see a sufficient effect of increasing solubility, and if it is outside the above-mentioned upper limit range, formulation stability may be affected.
- the coating base is a hydrophilic polymer, for example, polyvinylpyrrolidone (PVP), polyvinylacetate (PVA), hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose (sodium salt and calcium salt), ethylcellulose, Methylcellulose, hydroxyethylcellulose, ethylhydroxyethylcellulose, hydroxypropylcellulose (HPC), L-HPC (low-substituted HPC), polyvinyl alcohol, polymers of acrylic acid and salts thereof, vinylpyrrolidone-vinylacetate copolymers (eg Kollidon® VA64, BASF), Polycoat IR, gelatin, guar gum, partially hydrolyzed starch, alginates, xanthan, and these It may be one or more selected from the group consisting of a mixture of, but is not limited thereto. Preferably, it may be polyvinyl acetate (PVA) or hydroxypropylmethylcellulose (HPMC).
- PVP
- the coating base agent is, for example, in an amount of 0.2 to 10 parts by weight, preferably in an amount of 1 to 7 parts by weight, more preferably in an amount of 3 to 5 parts by weight based on 100 parts by weight of the tablet (uncoated tablet) before coating. can be used in any amount. If the coating base is less than the above-mentioned lower limit range, there may be a problem that the entire surface of the uncoated tablet is not completely covered with the coating base, and if it is outside the above-mentioned upper limit range, there may be an excessive delay problem of the dissolution rate.
- Example 1 Preparation of solid dispersion (weight ratio 1:1.5:0.25) of olaparib / Eudragit E / HPMC
- olaparib hydrate (crystalline form), 3.0 g of Eudragit E PO, and 0.1 g of TPGS were completely dissolved in 200 ml of EtOH. After completely dissolving 0.5 g of HPMC in 20 ml of water, olaparib and Eudragit E were uniformly mixed with the solution. The above mixed solution was spray dried to remove the solvent and a solid dispersion was obtained.
- Example 2 Preparation of solid dispersion (weight ratio 1:1:1) of olaparib/Eudragit E/HPMC
- Example 1 The solid dispersions of Examples 1, 2, and Comparative Example 1 were put in 150 ml of pH 1.2 buffer in an amount corresponding to 50 mg as olaparib, and shaken at 100 rpm in an incubator at 37° C. for 1 hour. After filtration of this test solution with an RC syringe filter (0.2 ⁇ m), 1 mL of this solution was added and diluted with 2 mL of diluent, and the content was measured according to the olaparib content analysis method, and the results are shown in Table 1 below.
- Test Example 2 Crystallinity evaluation by XRPD analysis
- the solid dispersions of Examples 1 and 2 and Comparative Example 1 were analyzed by XRPD to evaluate the crystallinity of olaparib in the solid dispersion.
- the XRPD patterns of the solid dispersions and olaparib API (raw material active ingredient) prepared in Examples 1 and 2 and Comparative Example 1, respectively, are shown in FIG. 1 .
- the XRPD pattern shown in FIG. 1 shows that while the olaparib API itself used for the preparation of the solid dispersion was in a crystalline form, all olaparib included in the solid dispersions prepared in Examples 1 and 2 and Comparative Example 1 were amorphous. .
- Example 1 The solid dispersions of Examples 1 and 2 and Comparative Example 1 were filled in an amount corresponding to 150 mg of olaparib in a hard gelatin capsule, put in an aluminum bag pouch together with a desiccant and sealed, and then accelerated conditions of 40°C, 75% RH It was stored for 6 months under the storage conditions of The dissolution rate change was observed by measuring the dissolution rate before storing the sample and 6 months after storage.
- a dissolution test was performed under the following conditions for the hard gelatin capsules filled with olaparib (150mg as olaparib). Samples were collected up to 60 minutes and the dissolution rate of the drug was measured through HPLC analysis.
- Test solution 450 ml pH 1.2 buffer
- Mannitol, fumaric acid, croscarmellose sodium and magnesium stearate were added to the solid dispersion of Example 1 in the following composition to prepare olaparib tablets.
- Mannitol, fumaric acid, croscarmellose sodium and magnesium stearate were added to the solid dispersion of Example 1 in the following composition to prepare olaparib tablets.
- Microcrystalline cellulose, fumaric acid, croscarmellose sodium and magnesium stearate were added to the solid dispersion of Example 1 in the following composition to prepare olaparib tablets.
- Test Example 4 Dissolution test of olaparib tablets
- Example 4 Comparative Example 2, and Comparative Example 3
- the dissolution rate with time in pH 1.2, pH 4.0, pH 6.8 buffer and water was measured, and the results are respectively shown in FIG. 2 , 3, 4, and 5 are shown. From FIGS. 2 to 5 , it can be confirmed that the tablets of Examples including the solid dispersion according to the present invention eluted more uniformly in all test solution conditions, compared to the tablets of Comparative Examples.
- Test solution pH 1.2, pH 4.0, pH 6.8 buffer, water (distilled water, DW) 450ml
- Dissolution reference time 5 minutes, 10 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes, 120 minutes
- Test Example 5 Pharmacokinetic (PK) test of olaparib tablets
- Example 3 In order to compare the in vivo kinetics of the tablets of Examples 3, 4, and Comparative Example 2 (formulations containing olaparib solid dispersion), a pharmacokinetic test was performed using a beagle dog as an experimental animal.
- the beagle dogs were divided into three groups and administered. Each formulation contains 150 mg as olaparib, and was orally administered to experimental animals maintained in a fasting state with 20 ml of water at 1 tablet/head dose. After administration, blood was collected at set time intervals up to 24 hours, and blood samples were stored frozen after separation of plasma. Plasma concentration-area under the time curve) and C max (peak plasma concentration) were calculated. The results are shown in Table 3 below.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (15)
- 올라파립; 폴리메타크릴레이트 공중합체; 및 셀룰로스계 고분자;를 포함하는 고체 분산체.
- 제1항에 있어서, 폴리메타크릴레이트 공중합체가 디메틸아미노에틸메타크릴레이트를 갖는 양이온성 고분자인, 고체 분산체.
- 제1항에 있어서, 폴리메타크릴레이트 공중합체가 폴리(부틸메타크릴레이트-co-(2-디메틸아미노에틸)메타크릴레이트-co-메틸메타크릴레이트)인, 고체 분산체.
- 제1항에 있어서, 셀룰로스계 고분자가 히드록시프로필메틸셀룰로스, 미결정질 셀룰로스, 히드록시프로필셀룰로스, 카르복시메틸셀룰로스, 에틸셀룰로스, 셀룰로스 아세테이트, 메틸셀룰로스 및 이들의 혼합물로 구성된 군으로부터 선택되는, 고체 분산체.
- 제1항에 있어서, D-α-토코페릴 폴리에틸렌 글리콜 숙시네이트를 더 포함하는, 고체 분산체.
- 제1항에 있어서, 분무 건조되어 얻어지는 것인, 고체 분산체.
- 제1항에 있어서, 무정형의 올라파립을 포함하는, 고체 분산체.
- (1) 올라파립을 폴리메타크릴레이트 공중합체와 함께 용매에 녹이거나 분산시키는 단계;(2) 상기 (1)단계에서 얻어진 용액 또는 분산액에 셀룰로스계 고분자를 첨가하고 혼합하는 단계; 및(3) 상기 (2)단계에서 얻어진 용액 또는 분산액으로부터 용매를 제거하는 단계;를 포함하는, 고체 분산체의 제조 방법.
- 제8항에 있어서, 용매의 제거가 분무 건조에 의하여 수행되는, 고체 분산체의 제조 방법.
- 제1항 내지 제7항 중 어느 한 항의 고체 분산체; 약제학적으로 허용 가능한 유기산; 및 약제학적으로 허용 가능한 희석제;를 포함하는, 경구용 조성물.
- 제10항에 있어서, 약제학적으로 허용 가능한 유기산이 아크릴산, 타르타르산, 시트르산, 말산, 말레인산, 푸마르산, 아세트산, 호박산, 젖산, 숙신산, 말론산, 글루타르산 및 이들의 혼합물로 구성된 군으로부터 선택되는, 경구용 조성물.
- 제10항에 있어서, 약제학적으로 허용 가능한 희석제가 수용성 희석제인, 경구용 조성물.
- 제12항에 있어서, 수용성 희석제가 당알코올류, 당류 및 이들의 혼합물로 구성된 군으로부터 선택되는, 경구용 조성물.
- 제10항에 있어서, 암 치료용인 경구용 조성물.
- 제1항 내지 제7항 중 어느 한 항의 고체 분산체와 약제학적으로 허용 가능한 유기산 및 약제학적으로 허용 가능한 희석제를 혼합하는 단계를 포함하는, 경구용 조성물의 제조 방법.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023533688A JP2023551917A (ja) | 2020-12-01 | 2021-12-01 | 安定性及び生体利用効率が改善されたオラパリブ固体分散体組成物 |
EP21900988.3A EP4257119A1 (en) | 2020-12-01 | 2021-12-01 | Olaparib solid dispersion composition with improved stability and bioavailability |
CN202180081119.4A CN116600827A (zh) | 2020-12-01 | 2021-12-01 | 具有改善的稳定性和生物利用度的奥拉帕尼固体分散体组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0166029 | 2020-12-01 | ||
KR20200166029 | 2020-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022119300A1 true WO2022119300A1 (ko) | 2022-06-09 |
Family
ID=81854208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/017964 WO2022119300A1 (ko) | 2020-12-01 | 2021-12-01 | 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4257119A1 (ko) |
JP (1) | JP2023551917A (ko) |
KR (1) | KR20220077094A (ko) |
CN (1) | CN116600827A (ko) |
WO (1) | WO2022119300A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115175668A (zh) * | 2019-12-20 | 2022-10-11 | 三养控股公司 | 具有改善的奥拉帕尼的溶解度和生物利用率的组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110066942A (ko) * | 2008-10-07 | 2011-06-17 | 아스트라제네카 유케이 리미티드 | 약학 제제 514 |
US20170105937A1 (en) * | 2015-10-16 | 2017-04-20 | Cadila Healthcare Limited | Olaparib co-precipitate and preparation method thereof |
KR20200045415A (ko) * | 2018-10-19 | 2020-05-04 | 주식회사 삼양바이오팜 | 아프레피탄트의 경구용 조성물 |
KR20200079957A (ko) * | 2018-12-26 | 2020-07-06 | 한국콜마주식회사 | 에독사반을 함유한 경구용 의약 조성물 및 그의 제조방법 |
-
2021
- 2021-11-30 KR KR1020210168721A patent/KR20220077094A/ko not_active Application Discontinuation
- 2021-12-01 EP EP21900988.3A patent/EP4257119A1/en active Pending
- 2021-12-01 JP JP2023533688A patent/JP2023551917A/ja active Pending
- 2021-12-01 WO PCT/KR2021/017964 patent/WO2022119300A1/ko active Application Filing
- 2021-12-01 CN CN202180081119.4A patent/CN116600827A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110066942A (ko) * | 2008-10-07 | 2011-06-17 | 아스트라제네카 유케이 리미티드 | 약학 제제 514 |
US20170105937A1 (en) * | 2015-10-16 | 2017-04-20 | Cadila Healthcare Limited | Olaparib co-precipitate and preparation method thereof |
KR20200045415A (ko) * | 2018-10-19 | 2020-05-04 | 주식회사 삼양바이오팜 | 아프레피탄트의 경구용 조성물 |
KR20200079957A (ko) * | 2018-12-26 | 2020-07-06 | 한국콜마주식회사 | 에독사반을 함유한 경구용 의약 조성물 및 그의 제조방법 |
Non-Patent Citations (1)
Title |
---|
FAN NA; MA PINGPING; WANG XIN; LI CHANG; ZHANG XIAORUI; ZHANG KEXIN; LI JING; HE ZHONGGUI: "Storage stability and solubilization ability of HPMC in curcumin amorphous solid dispersions formulated by Eudragit E100", CARBOHYDRATE POLYMERS, vol. 199, 21 July 2018 (2018-07-21), GB , pages 492 - 498, XP085448331, ISSN: 0144-8617, DOI: 10.1016/j.carbpol.2018.07.036 * |
Also Published As
Publication number | Publication date |
---|---|
KR20220077094A (ko) | 2022-06-08 |
CN116600827A (zh) | 2023-08-15 |
JP2023551917A (ja) | 2023-12-13 |
EP4257119A1 (en) | 2023-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018070671A1 (ko) | 레날리도마이드의 경구용 정제 조성물 | |
WO2013089479A1 (ko) | 세레콕시브 함유 고체분산체 및 그 제조방법 | |
WO2021125797A1 (ko) | 올라파립의 용해도 및 생체이용율이 개선된 조성물 | |
WO2022119300A1 (ko) | 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물 | |
EA036513B1 (ru) | Фармацевтические композиции, содержащие фениламинопиримидиновое производное | |
US20110086102A1 (en) | Delayed release compositions | |
WO2016013795A1 (ko) | 서방성 제제 | |
WO2019142207A1 (en) | Pharmaceutical compositions comprising ibrutinib | |
WO2022146007A1 (ko) | 에피나코나졸 경구용 조성물 | |
WO2019088662A1 (ko) | 수용해도 및 생체이용율이 개선된 소라페닙 나노입자 경구용 조성물 및 이의 제조 방법 | |
WO2021194253A1 (ko) | 포말리도마이드의 경구용 정제 조성물 및 이의 제조 방법 | |
WO2019199133A1 (ko) | 레날리도마이드의 경구용 코팅 정제 조성물 | |
WO2016072748A1 (en) | Pharmaceutical compositions comprising lobeglitazone for oral administration | |
KR102300335B1 (ko) | 아프레피탄트의 경구용 조성물 | |
JP7378393B2 (ja) | 改善された薬物製剤 | |
WO2019107989A1 (ko) | 피마살탄을 포함하는 고체 분산체 | |
WO2016052945A1 (en) | Granules containing oseltamivir, capsules comprising the granules, and method of preparing the capsules | |
WO2018203636A1 (ko) | 수용해도 및 생체이용율이 개선된 조성물 | |
WO2019107859A1 (ko) | 두타스테라이드가 봉입된 나노 가용화 다공체, 이를 포함하는 약학 조성물 및 이의 제조방법 | |
WO2019199132A1 (ko) | 다양한 용량의 레날리도마이드의 경구용 정제 조성물 | |
WO2018007556A1 (en) | Pharmaceutical solid dispersion of a bcl-2 inhibitor, pharmaceutical compositions thereof, and uses for the treatment of cancer | |
WO2016195377A2 (ko) | 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법 | |
KR102512866B1 (ko) | 아프레피탄트의 용해도가 증가된 경구용 조성물 | |
WO2018101681A1 (en) | Oral composite tablet comprising ezetimibe and rosuvastatin | |
EP4279075A1 (en) | A pharmaceutical composition comprising elagolix |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21900988 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180081119.4 Country of ref document: CN Ref document number: 2023533688 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021900988 Country of ref document: EP Effective date: 20230703 |